RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2
Project

Italy, Germany, France and the Netherlands signed with AstraZeneca the delivery contract of vaccines against COVID-19

Customers: European alliance of inclusive vaccines (IVA)

Pharmaceutics, medicine, health care

Contractors: AstraZeneca


Project date: 2020/06

In the middle of June, 2020 it became known that Italy, Germany, France and the Netherlands signed the contract with AstraZeneca company for delivery to the European citizens of vaccine against COVID-19 coronavirus.

This transaction became the first contract signed by the European alliance of inclusive vaccines (IVA). This group is called to provide faster delivery of perspective vaccines to all member states of alliance. The contract is expected 400 million doses. Vaccine was developed by AstraZeneca together with the University of Oxford and is already studied in clinical trials. This phase should come to the end in the fall, the Minister of Health of Italy Roberto Speranza on the Facebook page said. He added that in case of success the first batch of doses will come to Europe by the end of 2020.

Italy, Germany, France and the Netherlands concluded with AstraZeneca on supply of vaccines against COVID-19

The European Commission received from the governments of the European countries the mandate on negotiation about preliminary purchases of perspective koronavirusny vaccines, the high-ranking official of the EU in the field of health care reported, but till the last moment it was not clear whether there will be enough money for these purchases. Nevertheless, the Ministry of Health of Germany reported that at a meeting of Ministers of Health of the EU the European vaccinal alliance agreed to integrate the activity with activity of the EU Commission.

File:Aquote1.png
We hope to make this vaccine generally available in the shortest terms, - the chief executive of AstraZeneca Pascal Soriot said.
File:Aquote2.png

Astrazeneca signs production agreements and sale of the perspective vaccine worldwide that in case of the successful end of tests to produce 2 billion doses of vaccine by the end of 2020. Among other things the company signed contracts with two enterprises which are supported by Bill Gates, and the agreement for $1.2 billion with the U.S. Government.[1]

Notes